New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
07:27 EDTCBLICleveland BioLabs reports Q3 EPS (30c) vs (8c) in Q3 of 2011
Reports Q3 R&D expenses down to about $4.8M. Revenues for Q3 decreased to approximately $0.2M from approximately $3.8M in Q3 of 2011, primarily due to decreases in research sponsored by the DoD, BARDA and a NY State/RPCI Sponsored Research Agreement.
News For CBLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 24, 2015
17:41 EDTCBLICleveland BioLabs enters private placement worth approximately $25M
On June 24, Cleveland BioLabs entered into a definitive stock purchase agreement with an accredited investor, David Davidovich, a venture capital investor, pursuant to which the company agreed to issue and sell to the Purchaser, subject to customary closing conditions, an aggregate of 6,459,948 shares of the company’s common stock, par value $0.005 per share, for an aggregate purchase price of $24,999,998.76, or $3.87 per share. The company anticipates closing of the private placement to occur on or around July 6.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use